The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Meta-analysis on last ten years of clinical injection of bone marrow-derived and umbilical cord MSC to reverse cirrhosis or rescue patients with acute-on-chronic liver failure
Open accessAbstract
Background: Recent studies have shown that mesenchymal stem cell (MSC) therapy has potential therapeutic effects for patients with end-stage liver diseases. However, a consensus on the efficacy and safety of MSCs has not been reached. Methods: A systemic literature review was conducted by searching the Cochrane Library and PubMed databases for articles that evaluated the impact of MSC therapy on the outcomes among patients with end-stage liver disease. Various parameters, including pre- and post-treatment model of end-stage liver disease (MELD) score, serum albumin (ALB), total bilirubin (TB), coagulation function, aminotransferase, and survival rate, were evaluated. Results: This meta-analysis included a final total of 13 studies and 854 patients. The results indicated improved liver parameters following MSC therapy at different time points, including in terms of MELD score, TB level, and ALB level, compared with conventional treatment. Furthermore, the MSC treatment increased the overall survival rate among patients with liver cirrhosis and acute-on-chronic liver failure (ACLF). The changes in transaminase level and coagulation function differed between the different therapies at various post-treatment time points, indicating that MSC therapy provided no significant benefits in this regard. The further subgroup analysis stratified by liver background revealed that patients with ACLF benefit more from MSC therapy at most time points with improved liver function, including in terms of MELD score, TB level, and ALB level. In addition, no serious side effects or adverse events were reported following MSC therapy. Conclusions: The meta-analysis results suggest that MSC therapy is safe and results in improved liver function and survival rates among patients with end-stage liver disease. The subgroup analysis stratified by liver background indicated that patients with ACLF benefit more from MSC therapy than patients with liver cirrhosis at most time points.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Compared to intravenous infusion, intra-arterial and portal approaches necessitate an invasive angiographic procedure, which carries an increased risk of bleeding, vessel injury, and adverse effects.
“However, compared to intravenous infusion, these approaches necessitate an invasive angiographic procedure, which carries an increased risk of bleeding, vessel injury, and adverse effects [343, 348].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [348]
The Discussion (page unavailable) says hepatic arterial injection is invasive and carries a higher risk of bleeding than peripheral intravenous infusion. It does not address portal administration, specify an angiographic procedure, or identify vessel injury or other procedure-related adverse effects. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suk, K. T., Yoon, J., Kim, M. Y., Kim, C. W., Kim, J. K., Park, H., Hwang, S. G., Kim, D. J., Lee, B. S., Lee, S. H., et al. (2016) · Hepatology · doi:10.1002/hep.28693 · Cited by 303
Lin, B., Chen, J., Qiu, W., Wang, K., Xie, D., Chen, X., Liu, Q., Peng, L., Li, J., Mei, Y., et al. (2017) · Hepatology · doi:10.1002/hep.29189 · Cited by 288
El-Ansary, M., Abdel-Aziz, I., Mogawer, S., Abdel-Hamid, S., Hammam, O., Teaema, S., & Wahdan, M. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9322-y · Cited by 179
Shi, M., Li, Y.-Y., Xu, R.-N., Meng, F.-P., Yu, S.-J., Fu, J.-L., Hu, J.-H., Li, J.-X., Wang, L.-F., Jin, L., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10199-2 · Cited by 151
Flagged first, then by citations
Research works printed but not linked: 26
- Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell migration and tissue repair. Cells. 2019;8(8):784. · DOI
- Sun H, Shi C, Ye Z, Yao B, Li C, Wang X, et al. The role of mesenchymal stem cells in liver injury. Cell Biol Int. 2022;46(4):501–11. · DOI
- Jang YO, Cho MY, Yun CO, Baik SK, Park KS, Cha SK, et al. Effect of function-enhanced mesenchymal stem cells infected with decorin-expressing adenovirus on hepatic fibrosis. Stem Cells Transl Med. 2016;5(9):1247–56. · DOI
- Stock P, Bruckner S, Winkler S, Dollinger MM, Christ B. Human bone marrow mesenchymal stem cell-derived hepatocytes improve the mouse liver after acute acetaminophen intoxication by preventing progress of injury. Int J Mol Sci. 2014;15(4):7004–28. · DOI
- Zagoura DS, Roubelakis MG, Bitsika V, Trohatou O, Pappa KI, Kapelouzou A, et al. Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut. 2012;61(6):894–906. · DOI
- Watanabe Y, Tsuchiya A, Terai S. The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. Clin Mol Hepatol. 2021;27(1):70–80. · DOI
- Zhang K, Sun H, Cao H, Jia Y, Shu X, Cao H, et al. The impact of recipient age on the effects of umbilical cord mesenchymal stem cells on HBV-related acute-on-chronic liver failure and liver cirrhosis. Stem Cell Res Ther. 2021;12(1):466. · DOI
- Lim YL, Eom YW, Park SJ, Hong T, Kang SH, Baik SK, et al. Bone marrow-derived mesenchymal stem cells isolated from patients with cirrhosis and healthy volunteers show comparable characteristics. Int J Stem Cells. 2020;13(3):394–403. · DOI
- Wang L, Li J, Liu H, Li Y, Fu J, Sun Y, et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 2013;28(Suppl 1):85–92. · DOI · Paper page
- Jia Y, Shu X, Yang X, Sun H, Cao H, Cao H, et al. Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis. Stem Cell Res Ther. 2020;11(1):277. · DOI
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. · DOI · Paper page
- Li YH, Xu Y, Wu HM, Yang J, Yang LH, Yue-Meng W. Umbilical cord-derived mesenchymal stem cell transplantation in hepatitis B virus related acute-on-chronic liver failure treated with plasma exchange and entecavir: a 24-month prospective study. Stem Cell Rev Rep. 2016;12(6):645–53. · DOI
- Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011;54(3):820–8. · DOI
- Mohamadnejad M, Alimoghaddam K, Bagheri M, Ashrafi M, Abdollahzadeh L, Akhlaghpoor S, et al. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int. 2013;33(10):1490–6. · DOI · Paper page
- Salama H, Zekri AR, Medhat E, Al Alim SA, Ahmed OS, Bahnassy AA, et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res Ther. 2014;5(3):70. · DOI
- Schacher FC, Pezzi Martins, da Silva A, Silla L, Alvares-da-Silva MR. Bone marrow mesenchymal stem cells in acute-on-chronic liver failure grades 2 and 3: a phase I-II randomized clinical trial. Can J Gastroenterol Hepatol. 2021;20:3662776.
- Shi M, Zhang Z, Xu R, Lin H, Fu J, Zou Z, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 2012;1(10):725–31. · DOI
- Xu L, Gong Y, Wang B, Shi K, Hou Y, Wang L, et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. J Gastroenterol Hepatol. 2014;29(8):1620–8. · DOI
- Xu WX, He HL, Pan SW, Chen YL, Zhang ML, Zhu S, et al. Combination treatments of plasma exchange and umbilical cord-derived mesenchymal stem cell transplantation for patients with hepatitis B virus-related acute-on-chronic liver failure: a clinical trial in China. Stem Cells Int. 2019;2019:4130757. · DOI
- Zhang Z, Lin H, Shi M, Xu R, Fu J, Lv J, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 2012;27(Suppl 2):112–20. · DOI · Paper page
- Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: from liver transplantation to cell factory. J Hepatol. 2015;62(1 Suppl):S157–69. · DOI
- Zhou GP, Jiang YZ, Sun LY, Zhu ZJ. Therapeutic effect and safety of stem cell therapy for chronic liver disease: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2020;11(1):419. · DOI
- Carvalho JR, Verdelho MM. New insights about albumin and liver disease. Ann Hepatol. 2018;17(4):547–60. · DOI
- Zheng Y, Zhu S, Zheng X, Xu W, Li X, Li J, et al. Serum from acute-on-chronic liver failure patients may affect mesenchymal stem cells transplantation by impairing the immunosuppressive function of cells. J Clin Transl Hepatol. 2021;9(4):503–13.
- Belli LS, Duvoux C, Artzner T, Bernal W, Conti S, Cortesi PA, et al. Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). J Hepatol. 2021;75(3):610–22. · DOI
- Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med. 2017;6(6):1445–51. · DOI
Cited by
Sorted by citations
Shi, L., Zhang, Z., Mei, S., Wang, Z., Xu, Z., Yao, W., Liu, L., Yuan, M., Pan, Y., Zhu, K., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02318-4 · Cited by 16
Self-citationPan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2
“However, compared to intravenous infusion, these approaches necessitate an invasive angiographic procedure, which carries an increased risk of bleeding, vessel injury, and adverse effects [343, 348].”
Metadata
- Authors
- Wang, H., Yao, W., Wang, Y., Dong, H., Dong, T., Zhou, W., Cui, L., Zhao, L., Zhang, Y., Shi, L., & Jiang, Y.
- Affiliations
- Renmin Hospital of Wuhan University (CN)
- Hubei University of Technology (CN)
- Yangtze University (CN)
- Tianjin Medical University (CN)
- Chinese PLA General Hospital (CN)
- Corresponding author
- Zhang, Yu
- Shi, Lei
- Jiang, Yingan
- Venue
- Stem Cell Research & Therapy
- Published
- 2023-09-23
- Volume
- 14
- Issue
- 1
- Pages
- 267-267
- ISSN
- 1757-6512 (ISSN-L)
- PMC
- PMC10518116
- OpenAlex
- W4386993804
- Cited by
- 28
- References
- 4
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 5
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Stem Cell Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Innovation Platform for Academicians of Hainan Province (YSPTZX202216)
- National Clinical Center for Infectious Diseases, PLA General Hospital (NCRC-ID202105, 413FZT6)
- Science and Technology Project of Wuhan (2020020602012112)
- Haihe Laboratory of Cell Ecosystem Innovation Fund (HH22KYZX0046)
- Tianjin Free Trade Zone Innovation Development Project 211 (ZMCY-03-2021002-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Keywords
- mesenchymal stem cells, bone marrow-derived stem cells, umbilical cord-derived stem cells, liver cirrhosis, acute-on-chronic liver failure, end-stage liver disease, stem cell therapy, MELD score, serum albumin, total bilirubin, coagulation function, transaminases, overall survival, treatment safety
- MeSH terms
- Bone Marrow, Humans, Liver Cirrhosis, End Stage Liver Disease, Mesenchymal Stem Cells, Acute-On-Chronic Liver Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
